Tirzepatide

A dual GIP and GLP-1 receptor agonist, and one of the most studied weight and metabolic research compounds of the current incretin generation.

What it is

Tirzepatide (development code LY3298176) is a synthetic 39-amino-acid linear peptide that activates two incretin receptors from a single molecule: the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R). The peptide backbone is derived from the native GIP sequence and carries a C20 fatty diacid moiety attached through a linker. That lipid tail binds albumin and slows clearance, extending the circulating half-life to roughly five days and supporting once-weekly research dosing.

Because it engages both incretin pathways at once, tirzepatide is classed as a dual, or "twincretin", receptor co-agonist. It became a benchmark metabolic research compound after direct comparisons against single-pathway GLP-1 agonists such as semaglutide, and it is now a frequent point of reference for newer triple agonists like retatrutide. Supplied strictly for laboratory research use only, not for human or veterinary use.

How it works

Tirzepatide binds GIPR and GLP-1R, two class B G-protein-coupled receptors that regulate carbohydrate metabolism and appetite signalling. At the GIP receptor it behaves much like native GIP, while at the GLP-1 receptor it is a weaker but biased agonist: structural work reports that its affinity for GIPR is comparable to native GIP but roughly fivefold lower at GLP-1R than GLP-1 itself, making it an "imbalanced" dual agonist that favours GIPR. Cryo-EM structures show the peptide adopting an alpha-helical conformation with its N-terminus reaching deep into the transmembrane core of both receptors.

Downstream, receptor activation raises intracellular cAMP. At GLP-1R tirzepatide shows a bias toward cAMP signalling with reduced beta-arrestin recruitment and less agonist-induced receptor desensitisation than GLP-1, a property thought to help sustain the response. The combined GIP and GLP-1 signal is studied for glucose-dependent insulin secretion, slowed gastric emptying, and central effects on appetite and energy balance, which together drive the glycemic and body-weight changes seen in the trial literature below.

What the research shows

Tirzepatide has been characterised in the large phase 3 SURPASS programme (type 2 diabetes) and SURMOUNT programme (obesity). In the 72-week SURMOUNT-1 obesity trial published in the New England Journal of Medicine, once-weekly tirzepatide produced dose-dependent mean weight reductions of 15.0%, 19.5% and 20.9% at the 5, 10 and 15 mg doses versus 3.1% for placebo, with up to 91% of participants reaching at least 5% weight loss. In the 40-week SURPASS-2 trial it was compared head-to-head against semaglutide 1 mg and produced greater reductions in both HbA1c and body weight across all three doses.

Safety signals in the literature

Across the SURPASS and SURMOUNT trials the reported safety profile was consistent with the incretin class, with gastrointestinal effects (nausea, diarrhoea and vomiting) the most commonly recorded adverse events, generally mild to moderate and most frequent during dose escalation. These trial observations are noted here only as documented research findings and do not constitute clinical guidance.

Side Effects

Tirzepatide's side-effect profile is dominated by dose-related gastrointestinal effects, with a smaller set of serious labeled warnings. The figures below come from the FDA prescribing information for Mounjaro (type 2 diabetes) and Zepbound (obesity) on DailyMed, along with the pivotal SURPASS and SURMOUNT phase 3 trials. GI effects are common but usually mild to moderate and tend to appear during dose escalation, while the boxed and serious warnings are rare but clinically important. Rates run higher in the obesity trials, where doses are pushed to the maximum, than in the diabetes trials.

In short, the everyday side effects are the transient GI ones, nausea, diarrhea, vomiting and constipation, which are common, usually manageable, and tend to ease after dose escalation. The serious labeled warnings, the rodent thyroid C-cell tumor signal, pancreatitis, gallbladder disease, hypoglycemia in combination therapy, and dehydration-related kidney injury, are far less frequent but are the reason the drug carries a boxed warning and specific contraindications.

At a glance

Dosing

According to FDA prescribing information for Mounjaro (type 2 diabetes) and Zepbound (obesity), tirzepatide is given by subcutaneous injection once weekly and is started low to help the body adjust. Every patient begins at 2.5 mg once weekly for 4 weeks, a starting dose meant for tolerability rather than full effect, then moves up to 5 mg. From there the dose can be raised in 2.5 mg steps, waiting at least 4 weeks between increases, up to a maximum of 15 mg once weekly.

The stepwise increase exists mainly to reduce gastrointestinal side effects, which is why the 2.5 mg start is not counted as a treatment dose. Many people respond well at 5 or 10 mg, so an effective maintenance dose can be lower than the 15 mg maximum, as seen across the SURPASS and SURMOUNT trials (SURMOUNT-1, PubMed). This summary describes approved and studied regimens for educational, laboratory-research context only and is not medical advice or a dosing instruction.

Preparing it

Reconstitute the lyophilized powder with bacteriostatic or sterile water, added slowly down the side of the vial and swirled gently, never shaken, until fully dissolved. The volume of water you add determines the concentration of the finished solution, so decide your target concentration before drawing anything up.

For the full procedure see reconstitution, and to work out concentration per unit see concentration & math.

Where to go next

Last updated on July 3, 2026